Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 730,916
  • Shares Outstanding, K 13,685
  • Annual Sales, $ 195,890 K
  • Annual Income, $ 14,310 K
  • 60-Month Beta 1.02
  • Price/Sales 3.75
  • Price/Cash Flow 29.74
  • Price/Book 4.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.17
  • Number of Estimates 1
  • High Estimate 0.17
  • Low Estimate 0.17
  • Prior Year 0.48
  • Growth Rate Est. (year over year) -64.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
49.88 +5.19%
on 05/01/20
56.16 -6.57%
on 05/12/20
-1.29 (-2.40%)
since 04/28/20
3-Month
33.80 +55.24%
on 03/13/20
56.16 -6.57%
on 05/12/20
+6.57 (+14.31%)
since 02/28/20
52-Week
33.80 +55.24%
on 03/13/20
64.94 -19.20%
on 11/04/19
-0.40 (-0.76%)
since 05/28/19

Most Recent Stories

More News
Eagle Pharmaceuticals to Present at June Investor Conferences

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming...

EGRX : 52.50 (-1.70%)
Eagle Pharmaceut Has Returned 27.4% Since SmarTrend Recommendation (EGRX)

SmarTrend identified an Uptrend for Eagle Pharmaceut (NASDAQ:EGRX) on March 25th, 2020 at $41.66. In approximately 2 months, Eagle Pharmaceut has returned 27.39% as of today's recent price of $53.07.

EGRX : 52.50 (-1.70%)
Eagle Pharmaceuticals Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle") announced today that, due to public health and safety concerns related to the ongoing COVID-19 global pandemic, recommendations and orders from federal,...

EGRX : 52.50 (-1.70%)
Eagle Pharmaceut Has Returned 26.2% Since SmarTrend Recommendation (EGRX)

SmarTrend identified an Uptrend for Eagle Pharmaceut (NASDAQ:EGRX) on March 25th, 2020 at $41.66. In approximately 2 months, Eagle Pharmaceut has returned 26.16% as of today's recent price of $52.56.

EGRX : 52.50 (-1.70%)
Eagle Pharmaceuticals to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a fireside chat at...

EGRX : 52.50 (-1.70%)
Eagle Pharmaceuticals (EGRX) Q1 Earnings Surpass Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 78.72% and -3.63%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 52.50 (-1.70%)
Eagle Pharmaceuticals: 1Q Earnings Snapshot

WOODCLIFF LAKE, N.J. (AP) _ Eagle Pharmaceuticals Inc. (EGRX) on Monday reported a first-quarter loss of $2.9 million, after reporting a profit in the same period a year earlier.

EGRX : 52.50 (-1.70%)
Eagle Pharmaceuticals Reports First Quarter 2020 Results

-- Advanced novel fulvestrant product candidate, EA-114, which has the potential to enhance estrogen receptor ("ER") inhibition in advanced hormone-receptor ("HR")-positive breast cancer --

EGRX : 52.50 (-1.70%)
Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

TEVA : 13.04 (+1.01%)
RHHBY : 44.1970 (+2.57%)
AGN : 193.02 (+0.02%)
EGRX : 52.50 (-1.70%)
Why Eagle Pharmaceuticals (EGRX) Might Surprise This Earnings Season

Eagle Pharmaceuticals (EGRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

EGRX : 52.50 (-1.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade EGRX with:

Business Summary

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102,...

See More

Key Turning Points

2nd Resistance Point 55.44
1st Resistance Point 54.43
Last Price 52.50
1st Support Level 52.08
2nd Support Level 50.74

See More

52-Week High 64.94
Fibonacci 61.8% 53.04
Last Price 52.50
Fibonacci 50% 49.37
Fibonacci 38.2% 45.70
52-Week Low 33.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar